DexCom (DXCM) vs 3M (MMM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DexCom (DXCM) has outperformed 3M (MMM) over the past year, gaining 27.7% versus a gain of 4.4%. Over five years, MMM leads with a +6.6% price change compared with -38.1% for DXCM. 3M is the larger company by market cap ($83.61 billion vs $31.81 billion), about 2.6 times the size, while DexCom is growing revenue faster (+15.6% vs +1.5%).
On valuation, 3M trades at a lower forward P/E (16.5x vs 27.0x for DexCom). 3M pays a dividend yielding 1.86%, while DexCom does not currently pay one. DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 13.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | MMM |
|---|---|---|
| Share price | $84.30 | $162.12 |
| Market cap | $31.81B | $83.61B |
| 1-day change | +1.09% | -0.93% |
| YTD return | +27.02% | +1.26% |
| 1-year return | +27.67% | +4.37% |
| 5-year return | -38.07% | +6.57% |
| P/E ratio (TTM) | 33.45 | 28.80 |
| Forward P/E | 26.96 | 16.50 |
| EPS (TTM) | $2.52 | $5.63 |
| Dividend yield | 0.00% | 1.86% |
| Annual dividend | $0.00 | $3.02 |
| Revenue (latest FY) | $4.66B | $24.95B |
| Revenue growth (YoY) | +15.60% | +1.52% |
| Net income (latest FY) | $836.30M | $3.25B |
| Gross margin | 60.10% | 39.91% |
| Operating margin | 19.56% | 18.55% |
| Net margin | 17.94% | 13.03% |
| 52-week high | $92.59 | $184.90 |
| 52-week low | $54.11 | $139.34 |
| Distance from 52-week high | -8.95% | -12.32% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +14.15% | +15.51% |
| Average volume | 4.47M | 3.16M |
| Shares outstanding | 377.36M | 515.72M |
| Employees | 11,000 | 60,500 |
| Sector | Health Care | Industrials |
| Industry | Medical/Dental Instruments | Conglomerates |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 3M is about 2.6 times larger than DexCom by market value ($83.61B vs $31.81B).
- DXCM has outperformed MMM by 23.3 percentage points over the past year.
- 3M offers a meaningfully higher dividend yield (1.86% vs 0.00%).
- DexCom grew revenue faster in its latest fiscal year (+15.60% vs +1.52%).
- The two companies sit in different sectors: DexCom in Health Care and 3M in Industrials.
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About 3M
MMM stock →3M Company provides diversified technology services in the America, the Asia Pacific, Europe, the Middle East, Africa, and internationally. It operates through three segments: Safety and Industrial, Transportation and Electronics, and Consumer.
Industrials · Conglomerates · 60,500 employees
DXCM vs MMM FAQ
Which is bigger, DexCom or 3M?
3M (MMM) is larger, with a market capitalization of $83.61B compared with $31.81B for DexCom (DXCM).
Which stock has performed better over the past year, DXCM or MMM?
DXCM returned +27.67% over the past 12 months, compared with +4.37% for MMM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or MMM?
MMM has the lower trailing P/E at 28.8, versus 33.5 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, DexCom or 3M?
3M pays a dividend yielding 1.86%, while DexCom does not currently pay a regular dividend.
Are DexCom and 3M in the same industry?
No. DexCom is in the Health Care sector, while 3M is in Industrials.